Valuation: Collegium Pharmaceutical, Inc.

Market Cap 787M 713M 660M 595M 1.12B 74.19B 1.16B 7.92B 3.14B 39.63B 2.95B 2.89B 126B P/E 2026 *
24.3x
P/E 2027 * 11.6x
Enterprise Value 787M 713M 660M 595M 1.12B 74.19B 1.16B 7.92B 3.14B 39.63B 2.95B 2.89B 126B EV / Sales 2026 *
0.95x
EV / Sales 2027 * 0.93x
Free-Float
73.69%
Yield 2026 *
-
Yield 2027 * -
1 day+1.48%
1 week+4.58%
Current month+6.39%
1 month+12.48%
3 months-10.31%
6 months-27.30%
Current year-45.31%
1 week 23.99
Extreme 23.99
25.44
1 month 22.15
Extreme 22.151
26.39
Current year 21.43
Extreme 21.43
49.31
1 year 21.43
Extreme 21.43
50.79
3 years 21.43
Extreme 21.43
50.79
5 years 14.04
Extreme 14.04
50.79
10 years 7.37
Extreme 7.37
50.79
Manager TitleAgeSince
Chief Executive Officer 51 11/11/2024
Director of Finance/CFO 50 23/05/2021
Chief Tech/Sci/R&D Officer 65 22/03/2022
Director TitleAgeSince
Chairman 69 14/05/2025
Director/Board Member 72 31/01/2014
Director/Board Member 78 31/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
18/05/26 Sell

Director

-20 0.0001%
15/05/26 Exercice

Director

21,527 0.0664%
14/05/26 Free

Director

8,741 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+4.58%-44.93%+0.84% 787M
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.39%+2.33%+27.36%+75.11% 430B
Weighted average by Cap. +0.54%+3.26%+37.68%+96.48%

Financials

2026 *2027 *
Net sales 832M 754M 697M 629M 1.19B 78.44B 1.23B 8.38B 3.32B 41.9B 3.12B 3.06B 133B 848M 768M 711M 641M 1.21B 79.93B 1.25B 8.54B 3.38B 42.7B 3.18B 3.11B 136B
Net income 41.92M 37.99M 35.14M 31.7M 59.75M 3.95B 61.85M 422M 167M 2.11B 157M 154M 6.7B 80.65M 73.09M 67.6M 60.99M 115M 7.6B 119M 812M 322M 4.06B 303M 296M 12.89B
Net Debt - -
Projected Income Statement - Annual - Collegium Pharmaceutical, Inc.
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
423
Date Price Change Volume
13/11/26 US$25.32 +1.48% 395,544
12/11/26 US$24.95 +0.56% 479,894
11/11/26 US$24.81 +1.39% 500,401
10/11/26 US$24.47 -0.97% 851,839
09/11/26 US$24.71 +2.07% 628,849
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Collegium Pharmaceutical, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
25.32USD
Average target price
44.00USD
Spread / Average Target
+73.78%
  1. Stock Market
  2. Stocks
  3. COLL Stock